1. The landscape of new drugs in extranodal NK/T-cell lymphoma
   Liang Wang et al, 2020, Cancer Treatment Reviews CrossRef
2. STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner.
   Shanshan Sun et al, 2018, Clin Cancer Res CrossRef
3. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma
   Meiyu Chen et al, 2021, International Immunopharmacology CrossRef
4. Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt–β-catenin–STAT3 signaling
   Shunfeng Hu et al, 2021, Cell Death Differ CrossRef
5. Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
   Ka-Hei (Murphy) Sun et al, 2022, Diagnostics CrossRef
6. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma
   John de Groot et al, 2022, CNS Oncology CrossRef
7. null
   David J. Feith et al, 2023 CrossRef
8. Oxymatrine ameliorates rheumatoid arthritis by regulation of Tfr/Tfh cell balance via the TLR9‐MyD88‐STAT3 signaling pathway
   Gan Cao et al, 2023, J Sci Food Agric CrossRef
9. Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade?
   Renata de Oliveira Costa et al, 2023, Front. Oncol. CrossRef
10. Novel target and treatment agents for natural killer/T-cell lymphoma
    Xiao-Peng Tian et al, 2023, J Hematol Oncol CrossRef
11. null
    Yuan Tan et al, 2024 CrossRef